181 related articles for article (PubMed ID: 21449604)
1. Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers.
Loo L; Capobianco JA; Wu W; Gao X; Shih WY; Shih WH; Pourrezaei K; Robinson MK; Adams GP
Anal Chem; 2011 May; 83(9):3392-7. PubMed ID: 21449604
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Kontani K; Kuroda N; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Kushida Y; Date M; Haba R; Houchi H; Yamauchi A; Yokomise H
Cancer Biol Ther; 2013 Jan; 14(1):20-8. PubMed ID: 23114645
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in nanomaterials-based electrochemical immunosensors and aptasensors for HER2 assessment in breast cancer.
Ahirwar R
Mikrochim Acta; 2021 Sep; 188(10):317. PubMed ID: 34476602
[TBL] [Abstract][Full Text] [Related]
4. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
5. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Perrier A; Gligorov J; Lefèvre G; Boissan M
Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
[TBL] [Abstract][Full Text] [Related]
6. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
7. Preparation and application of immunoaffinity in-tube solid phase microextraction column with oriented antibody-immobilized porous layer open tubular capillary for high sensitive quantification of serum extracellular domain of human epidermal growth factor receptor 2 levels.
Pan J; Song Y; Xu B; Liu J; Fu L; Xu L
J Chromatogr A; 2020 May; 1619():460974. PubMed ID: 32087879
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
9. Quantum dots as nanolabels for breast cancer biomarker HER2-ECD analysis in human serum.
Freitas M; Neves MMPS; Nouws HPA; Delerue-Matos C
Talanta; 2020 Feb; 208():120430. PubMed ID: 31816682
[TBL] [Abstract][Full Text] [Related]
10. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
[TBL] [Abstract][Full Text] [Related]
11. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
12. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
Eppenberger-Castori S; Klingbiel D; Ruhstaller T; Dietrich D; Rufle DA; Rothgiesser K; Pagani O; Thürlimann B
BMC Cancer; 2020 Feb; 20(1):114. PubMed ID: 32046665
[TBL] [Abstract][Full Text] [Related]
13. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer.
Petersen ER; Sørensen PD; Jakobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1483-92. PubMed ID: 23420288
[TBL] [Abstract][Full Text] [Related]
14. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
15. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Fornier MN; Seidman AD; Schwartz MK; Ghani F; Thiel R; Norton L; Hudis C
Ann Oncol; 2005 Feb; 16(2):234-9. PubMed ID: 15668276
[TBL] [Abstract][Full Text] [Related]
16. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
17. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
18. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
[TBL] [Abstract][Full Text] [Related]
19. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
[TBL] [Abstract][Full Text] [Related]
20. Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels.
Fabricio ASC; Michilin S; Zancan M; Agnolon V; Peloso L; Dittadi R; Scapinello A; Ceccarelli C; Gion M
Scand J Clin Lab Invest; 2019 Jul; 79(4):260-267. PubMed ID: 30982358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
